Company Overview and News

0
List of stocks on SEBI’s ‘monitor list’ was leaked, suspect traders

2018-06-05 thehindubusinessline
Was a list of stocks that were to be included in Additional Surveillance Measure (ASM), the new category formed by SEBI to check market manipulation, leaked to operators ahead of its official release? A section of stock market brokers and top traders suspect that operators in Mumbai and Gujarat may have had access to the list on May 31 before it was officially put up on stock exchange websites.
517421 ALNSE 500339 513269 MANINDS 533333 RAIN 532497 FCL RADICO BUTTERFLY EXCELINDUS 500650

4
Market Live: Sensex at day#39;s high, Nifty reclaims 10,700; LT up 2% ahead of Q4 nos

2018-05-28 moneycontrol
Buzzing: Capacit’e Infraprojects share price rallied nearly 4 percent after Edelweiss Securities has initiated coverage with Buy rating on the stock and target price of Rs 397.
524715 INDIANB TORNTPHARM MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 GLKQY PRAJIND 532461 500850 INDHOTEL 500650 GLENMARK 522205 514043 INDIGO JETAIRWAYS 533023 532865 539207 TECHM 539448 M30 PNJZY 532296 TQRRY 500420 SUNPHARMA PNB WABCOINDIA EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex at day#39;s high, Nifty inches towards 10,700; LT up 2% ahead of Q4 nos

2018-05-28 moneycontrol
Market Update: The market is trading at day's high, with the Nifty inching towards 10,700 levels following sharp correction in crude oil prices and appreciation in the rupee.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 GLKQY PRAJIND 532461 500650 GLENMARK 522205 514043 INDIGO JETAIRWAYS 533023 532865 539207 TECHM 539448 M30 PNJZY 532296 SUNPHARMA PNB WABCOINDIA EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex strong, Midcap index up over 1%; Nifty IT underperforms

2018-05-28 moneycontrol
Market Update: The market continued to trade strong for the third consecutive day today, with the Sensex rising more than 150 points. Steep fall in crude oil prices and recovery in the rupee from 18-month low boosted investors sentiment.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 PRAJIND 532461 500650 522205 514043 INDIGO JETAIRWAYS 532865 539207 TECHM 539448 M30 PNJZY SUNPHARMA PNB EXCELINDUS MANPASAND MEGH

0
Excel Industries Limited - Financial Result Updates

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
EXCELINDUS 500650

4
Market Live: Sensex up 200 pts, Midcap extends gains; Manpasand Beverages dips 20%

2018-05-28 moneycontrol
Dr Reddy's Laboratories files lawsuit in US District Court: Shares of Dr Reddy's Laboratories rose 1.3 percent as company filed lawsuit in the United States District Court.
524715 INDIANB MGHOF 532617 HIMATSEIDE 532814 TCHQY 532755 PRAJIND 532461 500650 522205 514043 INDIGO JETAIRWAYS 532865 539207 TECHM 539448 M30 PNJZY SUNPHARMA PNB EXCELINDUS MANPASAND MEGH

4
Market Live: Sensex reclaims 35K, opens up 100 pts; sharp fall in oil prices lift IOC, HPCL, BPCL

2018-05-28 moneycontrol
Rupee Update: The rupee strengthened by 39 paise to 67.39 against the dollar at the interbank forex market today on fresh selling of the greenback by exporters and banks.
522205 524715 INDIANB INDIGO 514043 MGHOF 532617 HIMATSEIDE 532814 JETAIRWAYS TCHQY 532865 532755 539448 TECHM PRAJIND M30 PNJZY 532461 SUNPHARMA PNB EXCELINDUS MEGH 500650

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...